Yifan Pharmaceutical
Launch date
Employees
Market cap
CAD2.3b
Enterprise valuation
CAD2.6b (Public information from Sep 2024)
Share price
CNY10.19 002019.SZ
Hangzhou Zhejiang (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.4b | 4.4b | 3.8b | 4.1b | 5.4b | 6.4b | 7.4b |
| % growth | 4 % | (18 %) | (13 %) | 6 % | 32 % | 19 % | 15 % |
| EBITDA | 1.4b | 556m | 628m | 441m | 838m | 1.1b | 1.3b |
| % EBITDA margin | 25 % | 13 % | 16 % | 11 % | 16 % | 17 % | 17 % |
| Profit | 968m | 278m | 191m | (551m) | 551m | 774m | 930m |
| % profit margin | 18 % | 6 % | 5 % | (14 %) | 10 % | 12 % | 13 % |
| EV / revenue | 4.3x | 4.9x | 3.9x | 4.4x | 2.5x | 2.1x | 1.8x |
| EV / EBITDA | 17.2x | 39.1x | 23.9x | 40.8x | 15.8x | 12.2x | 10.4x |
| R&D budget | 325m | 197m | 190m | 312m | - | - | - |
| R&D % of revenue | 6 % | 4 % | 5 % | 8 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | - | |
| N/A | N/A | IPO | |
| Total Funding | - | ||
